SCHEMBL6319248

SCHEMBL6319248

CNC(=O)[C@@H](Cc1cccs1)N(C)C(=O)[C@@H](Cc1csc2ccccc12)N(C)C(=O)COCC(C)(C)N

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
MMP8 P22894 2/20 0.36
CTSL P07711 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
TACR1 P25103 1/20 0.35
CTSC P53634 1/20 0.34
POLB P06746 2/20 0.34
HPGD P15428 1/20 0.34
GHSR Q92847 3/20 0.33
OPRD1 P41143 3/20 0.33
KLKB1 P03952 2/20 0.32
KLK1 P06870 1/20 0.32
OPRM1 P35372 2/20 0.32
OPRK1 P41145 2/20 0.32
MC4R P32245 1/20 0.31
F10 P00742 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324008 0.90 CTSL (0.39) MMP2MMP9MMP8CTSLCTSS
SCHEMBL6318098 0.88 MMP2 (0.36) MMP2MMP9MMP8CTSLCTSS
SCHEMBL6323968 0.88 TACR1 (0.37) MMP2MMP9MMP8CTSLCTSS
SCHEMBL6318207 0.86 KLKB1 (0.39) MMP2MMP9MMP8CTSLCTSS
SCHEMBL6317191 0.84 GHSR (0.49) CTSSCTSKCTSCGHSRKLKB1
SCHEMBL7063361 0.84 MMP2 (0.35) MMP2MMP9MMP8CTSLCTSS
SCHEMBL6326451 0.82 GHSR (0.51) MMP2MMP9MMP8CTSLCTSS
SCHEMBL6324912 0.82 GHSR (0.50) MMP9MMP8CTSCGHSR
SCHEMBL6326460 0.82 GHSR (0.51) MMP2MMP9MMP8CTSLCTSS
SCHEMBL6324203 0.82 GHSR (0.35) CTSSCTSKCTSCGHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US claimed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US claimed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 MMP2 2439/4885MMP9 2831/4885MMP8 4280/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR MMP2 2624/4885MMP9 3090/4885MMP8 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.